180 related articles for article (PubMed ID: 38275613)
1. The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting.
Wang W; Li W; Zhang D; Mi Y; Zhang J; He G
Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38275613
[No Abstract] [Full Text] [Related]
2. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
3. Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.
Li J; Yang Z; Wang T; Li M; Wu X; Fu X; Yang C; Li Y; Wang X; Lan Z; Li M; Chen S
BMC Cancer; 2024 May; 24(1):667. PubMed ID: 38822303
[TBL] [Abstract][Full Text] [Related]
4. Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study.
Xie W; Li J; Du H; Xia J
Arthritis Res Ther; 2023 Aug; 25(1):148. PubMed ID: 37580807
[TBL] [Abstract][Full Text] [Related]
5. Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.
Ding W; Chen L; Xia J; Pei B; Song B; Li X
Medicine (Baltimore); 2024 May; 103(18):e38010. PubMed ID: 38701318
[TBL] [Abstract][Full Text] [Related]
6. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
Miao L; Miao T; Zhang Y; Hao J
BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
[TBL] [Abstract][Full Text] [Related]
7. Sex and statin-related genetic associations at the PCSK9 gene locus: results of genome-wide association meta-analysis.
Pott J; Kheirkhah A; Gadin JR; Kleber ME; Delgado GE; Kirsten H; Forer L; Hauck SM; Burkhardt R; Scharnagl H; Loeffler M; März W; Thiery J; Gieger C; Peters A; Silveira A; Hooft FV; Kronenberg F; Scholz M
Biol Sex Differ; 2024 Mar; 15(1):26. PubMed ID: 38532495
[TBL] [Abstract][Full Text] [Related]
8. Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.
Huang Q; Zhang Q; Cao B
Brain Behav; 2024 Jun; 14(6):e3543. PubMed ID: 38837845
[TBL] [Abstract][Full Text] [Related]
9. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
10. Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations.
Ardissino M; Slob EAW; Reddy RK; Morley AP; Schuermans A; Hill P; Williamson C; Honigberg MC; de Marvao A; Ng FS
Eur J Prev Cardiol; 2024 Jun; 31(8):955-965. PubMed ID: 38294056
[TBL] [Abstract][Full Text] [Related]
11. Causal association between lipid-lowering drugs and female reproductive endocrine diseases: a drug-targeted Mendelian randomization study.
Zhao J; Wang R; Song L; Han H; Wang P; Zhao Y; Zhang Y; Zhang H
Front Endocrinol (Lausanne); 2023; 14():1295412. PubMed ID: 38027179
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
[TBL] [Abstract][Full Text] [Related]
13. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.
Rosoff DB; Bell AS; Jung J; Wagner J; Mavromatis LA; Lohoff FW
J Am Coll Cardiol; 2022 Aug; 80(7):653-662. PubMed ID: 35953131
[TBL] [Abstract][Full Text] [Related]
14. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug-Target Mendelian Randomization Study.
Bell AS; Rosoff DB; Mavromatis LA; Jung J; Wagner J; Lohoff FW
J Am Heart Assoc; 2022 Nov; 11(21):e026122. PubMed ID: 36285785
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction.
Sun Z; Yun Z; Lin J; Sun X; Wang Q; Duan J; Li C; Zhang X; Xu S; Wang Z; Xiong X; Yao K
J Transl Med; 2024 Apr; 22(1):404. PubMed ID: 38689297
[TBL] [Abstract][Full Text] [Related]
17. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
Tan Z; Hong J; Sun A; Ding M; Shen J
Front Endocrinol (Lausanne); 2023; 14():1301163. PubMed ID: 38107516
[TBL] [Abstract][Full Text] [Related]
18. Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.
Pott J; Schlegel V; Teren A; Horn K; Kirsten H; Bluecher C; Kratzsch J; Loeffler M; Thiery J; Burkhardt R; Scholz M
Circ Genom Precis Med; 2018 May; 11(5):e001992. PubMed ID: 29748315
[TBL] [Abstract][Full Text] [Related]
19. Association between lipid-lowering drugs and allergic diseases: A Mendelian randomization study.
Xu Y; Li Y
World Allergy Organ J; 2024 Apr; 17(4):100899. PubMed ID: 38623319
[TBL] [Abstract][Full Text] [Related]
20. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
